2 unknown, 1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 2 | Unknown 2 |
Follow OrsoBio, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects TLC-1180 Oral Solution, TLC-1180 Tablet, Placebo Oral Solution - Healthy Participants | Phase 1 | Recruiting | OrsoBio, Inc | 332 | 2025-10-20 | 2026-08-21 |
| Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD TLC-2716 Dose 1, TLC-2716 Dose 2, Placebo - Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease | Phase 2 | Unknown | OrsoBio, Inc | 30 | 2024-08-12 | 2025-04-03 |
| Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes TLC-6740 Oral Solution, Placebo Oral Solution, TLC-6740 Tablet - Healthy Subjects, Obesity | Phase 1 | Active not recruiting | OrsoBio, Inc | 564 | 2023-04-22 | 2026-08-21 |
| A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance TLC-3595 Dose 1, TLC-3595 Dose 2, Placebo - Insulin Resistance | Phase 2 | Unknown | OrsoBio, Inc | 76 | 2023-03-08 | 2024-08-20 |
| A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants TLC-2716, Placebo - Healthy Subjects | Phase 1 | Completed | OrsoBio, Inc | 100 | 2022-09-09 | 2024-05-20 |
Diabetes Mellitus, Type 2 (1) · Hypertriglyceridemia (1) · Insulin Resistance (1) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1)
Tirzepatide (1)
New Zealand (4) · Mexico (1)